Status:

RECRUITING

Comparative Head Lice Therapy With Dimet 5® vs. Hedrin® Once

Lead Sponsor:

Infectopharm Arzneimittel GmbH

Conditions:

Head Lice Infestation

Pediculosis Capitis

Eligibility:

All Genders

6-18 years

Brief Summary

Randomized, investigator-blinded, controlled, multicenter comparative study on the treatment of acute head lice infestation in children with 2 dimeticone preparations with different application times ...

Eligibility Criteria

Inclusion

  • Acute head lice infestation
  • Age ≥ 6 months
  • Adequate informed consent for study participation:
  • Age-appropriate informed consent and verbal informed consent from the patient (if capable of both).
  • Written informed consent from the legal guardian(s) (written and verbal).

Exclusion

  • Adults (≥ 18 years of age)
  • Known hypersensitivity to any component of the test or comparator product.
  • Scalp lice therapy in the previous 2 weeks (with an appropriate drug or medical device).
  • Severe disease of the scalp or injuries/open wounds on the hairy head
  • Secondary infection in the area of the hairy head
  • Treatment with cotrimoxazole or trimethoprim in the last 4 weeks or new treatment to be initiated now
  • Other relevant reasons, e.g. diseases or dysfunctions, which, in the opinion of the investigator, militate against the inclusion of the patient in the study (including risk factors for severe COVID-19 disease in the case of SARS-CoV-2 infection)
  • Simultaneous participation of another household member in the trial.
  • Previous participation in this trial
  • Participation in another trial within the last 30 days
  • Inability of the legal guardian(s) to understand the study content and instructions.
  • Limited legal capacity of the legal guardian(s)
  • Apparent unreliability or unwillingness to cooperate on the part of the legal guardian(s)
  • Known alcohol, medication or drug dependency of the legal guardian(s)
  • Dependence of the patient or guardian on the sponsor or investigator.

Key Trial Info

Start Date :

May 17 2021

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

March 1 2026

Estimated Enrollment :

240 Patients enrolled

Trial Details

Trial ID

NCT04878276

Start Date

May 17 2021

End Date

March 1 2026

Last Update

March 6 2024

Active Locations (26)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 7 (26 locations)

1

Dr. med. Thilo Heising

Aalen, Germany

2

Gemeinschaftspraxis Gilb/Bauer/von Bentzel

Augsburg, Germany

3

Dr. med. Omar Esteban Fernandez Salgueiro

Balingen, Germany

4

Dr. med. Martin Wiesner

Berlin, Germany